TX-MARY-KAY
10.6.2019 08:02:10 CEST | Business Wire | Press release
Mary Kay Inc., a global beauty company and leader in skin care innovation, continues its ongoing support of the beauty and scientific communities by participating in two major global conferences in Europe this month: the 24th World Congress of Dermatology (WCD), June 10–15 in Milan, Italy and the 5th Future of Formulations in Cosmetics Summit, June 19-20, in Dusseldorf, Germany.
Held every four years, the World Congress of Dermatology is the largest dermatology meeting in the world. The WCD’s 2019 theme, “A New Era for Global Dermatology,” was the perfect match for Mary Kay to present its applied science findings and continue the scientific conversation around pollution and skin damage. On June 12, Mary Kay will host a symposium at the event titled “Environmental Stressors and Skin: Beyond UV.”
The symposium will explore the impact of external environmental aggressors on skin health, with a focus on Europe and how antioxidants can help reduce the damaging effects of pollution. Moderated by Michelle Hines, Ph.D., Director, Global Upstream Research & Technology at Mary Kay, the symposium will feature two renowned European skin experts:
- Jean Krutmann , M.D., Professor & Director at Leibniz Research Institute for Environmental Medicine – Dusseldorf, Germany.
- Stefanie Williams, M.D., Dermatologist & Medical Director at EUDELO – London, United Kingdom.
The extent of air pollution’s impact on skin and overall health was recently revealed in a new comprehensive global review by the Forum of International Respiratory Societies’ Environmental Committee, that reported air pollution may potentially affect every organ in the human body.* The report is especially relevant to the European region, as many European cities have been found to exceed air pollution limits set by the World Health Organization (WHO) or the European Environment Agency (EEA).
In fact, more than 40 towns and cities in the UK alone exceed WHO air pollution limits** and the EEA named 15 cities that are worst affected by dust particle, nitrogen dioxide and sulfur dioxide pollution*** in Germany. Excessive levels of pollution have adverse impact on overall health and are also detrimental to skin health, texture and appearance.
A pioneer of environmental medicine, Professor Krutmann has been relentlessly working in the field of skin protection. “Since I discovered in 2010 that air pollution causes skin aging and skin pigmentation, my institute has conducted a lot of research to verify this observation and to unravel the underlying mechanisms. From these studies it is now clear that long term exposure to traffic-related particulate matter (PM) is not only dangerous for our lungs and cardiovascular system, but skin health is compromised as well,” stated Jean Krutmann, M.D.
Stefanie Williams, M.D., further explained: “We might not be able to separate the damage caused to the skin by UV exposure from those caused by air pollution clinically; however, given the major research advances made in skin and air pollution science, my expectation is that the adverse effects of pollution on skin health will continue to have a growing impact in the future in high-density cities," explained Dr. Williams.
During Mary Kay’s presentation at the 5th Future of Formulations in Cosmetics Summit, Michelle Hines, Ph. D. will reveal Mary Kay’s latest research on an antioxidant complex that helps delay the onset of premature signs of skin aging related to the damaging effects of diesel exhaust particles (DEP). The breakthrough technology, found in the Mary Kay® TimeWise® Miracle Set 3D™ skin care line, provides a powerful free-radical fighting regimen with an exclusive, patent-pending, three-dimensional approach to skin aging.
“Experts have confirmed the significant negative impact of air pollution on skin and this impact will continue to grow as environmental stressors, such as DEP, and pollution levels increase, especially in densely populated urban areas,” Dr. Hines noted. “Mary Kay has discovered targeted technologies that help delay the onset of premature skin aging from unavoidable environmental and lifestyle stressors. Simultaneously, Mary Kay has been advancing scientific discussions with renowned experts around the globe to drive awareness on the negative impact of pollution on skin.”
As one of the world’s leading cosmetics and skincare industry innovators, Mary Kay’s participation in the 24th World Congress of Dermatology and the 5th Future of Formulations in Cosmetics Summit, are the latest installments in a series of global partnerships with the scientific and academic international communities.
Further demonstrating its long-lasting commitment to funding and contributing to skin health research, Mary Kay has also presented research on the topic of skin and pollution in North America at the International Investigative Dermatology meeting in May 2018, in Orlando, Florida, and in Latin America at the Reunion Anual de Dermatologos Latinoamericanos , in May 2019, in Buenos Aires, Argentina.
Every year, Mary Kay invests millions of dollars in research and development, and conducts hundreds of thousands of scientific tests on products and ingredients to ensure the highest standards of safety, quality and performance. Mary Kay holds more than 1,500 patents for products, technologies and packaging designs in its global portfolio.
*Review by the Forum of International Respiratory Societies’
Environmental Committee, Part 1: The Damaging Effects of Air Pollution
(February 2019)
** WHO Global Ambient Air Quality Database
(update 2018)
***Report by
Bundesministerium für Umwelt, Naturschutz, Bau und Reaktorsicherheit,
Berlin, Germany. 2015 (Translation: Federal Ministry for Environment,
Nature Conservation, and Nuclear Safety).
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company more than 55 years ago with three goals: develop rewarding opportunities for women, offer irresistible products, and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skin care, color cosmetics and nutritional supplements. Through the Mary Kay Foundation™, the company has awarded more than $78 million to cancer research and causes to help end domestic violence. Mary Kay Ash’s original vision continues to shine—one lipstick at a time. Learn more at www.marykay.com
About the WCD Meeting
The World Congress of Dermatology (WCD) - is the largest Dermatology meeting in the world. It is held every four years on various continents. The 24th WCD was held in Milano and hosted by the Italian Society of Dermatology (SIDeMaST) from June 10-15, 2019 under the auspices of the International League of Dermatological Societies. It has been over 40 years since Milan last hosted the WCD. The Meeting focused on major breakthroughs and advances in Dermatology, ranging from clinical practice to research, technology and innovation. Learn more at www.wcd2019milan.org
About the 5th Future of Formulations in Cosmetics Summit
The 5th Future of Formulations in Cosmetics Summit brings together senior executives and experts from raw materials and active ingredients manufacturers, chemical companies, major associations, technology companies, brand owners, cosmetic companies, testing companies to discuss the latest changes, challenges and developments within the industry. The 5th Future of Formulations in Cosmetics Summit will be held in Dusseldorf in Germany on June 19-20, 2019.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190609005044/en/
Contact:
Mary Kay Inc. Corporate Communications marykay.com/newsroom 972.687.5332 or media@mkcorp.com
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
Sutherland Launches FinAI Hub to Industrialize Agentic AI for Banking and Financial Services6.3.2026 14:00:00 CET | Press release
A domain-trained AI agent workforce enables production-scale AI across regulated financial institution operations Today, Sutherland announced the launch of Sutherland FinAI Hub, an enterprise Agentic AI platform built exclusively for Banking and Financial Services. As financial institutions accelerate AI adoption, many initiatives remain confined to pilots, unable to scale across legacy systems and core operations. Sutherland FinAI Hub is designed to help close that gap. FinAI Hub is an innovation ecosystem where Sutherland works with clients to design, prototype, and scale Agentic AI workflows across core operations. At launch, the platform brings together a large and expanding workforce of domain-trained AI agents purpose-built for financial institutions, supporting functions across retail banking, payments, cards, consumer and commercial lending, servicing, back office, risk and compliance functions. These modular agents can operate independently or be orchestrated across end-to-end
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
